One of our clients published preclinical data on NASH-fibrosis on Journal of Cellular and Molecular Medicine
We announced that the results of a study in the STAM™ mouse model of NASH performed by SMC Laboratories Inc. has been published in Journal of Cellular and Molecular Medicine by Pharmaxis Ltd.:
Title: “The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis”
Lysyl oxidases regulate many biological processes including extracellular matrix stabilization, cellular growth and homeostasis. Their protein expression has been positively correlated with fibrosis in several organs.
PXS-5153A, dual LOX2/LOXL3 inhibitor, treatment reduced liver fibrosis and hepatocyte ballooning (NASH disease score) demonstrating the hepatoprotective effects of the compound.
Please let me know if you would like further information on our services.